8 hasil untuk "Shanu Modi"

Unlocking the potential of antibody–drug conjugates for cancer therapy

Joshua Z. Drago; Shanu Modi; Sarat Chandarlapaty

Nature Reviews Clinical Oncology · 2021 · Inggris · OpenAlex Scopus

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Paolo Tarantino; Roberto Carmagnani Pestana; Chiara Corti dkk.

CA A Cancer Journal for Clinicians · 2021 · Inggris · OpenAlex Scopus

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify tumors by more than their histology has been proposed, and therapies are now tailored to treat cancers based on specific molecular aberrations and immunologic markers. In fact, multiple histology-agnostic…

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

Charles Arthur Powell; Shanu Modi; Hiroji Iwata dkk.

ESMO Open · 2022 · Inggris · OpenAlex Scopus

INTRODUCTION: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. METHODS: Patients who received T-DXd across nine studies were included…

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi; Haeseong Park; Rashmi Krishna Murthy dkk.

Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

PURPOSE: Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in patients…

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Chiaojung Jillian Tsai; Jonathan T. Yang; Narek Shaverdian dkk.

The Lancet · 2023 · Inggris · OpenAlex

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Tarantino; Giulia Viale; Michael F. Press dkk.

Annals of Oncology · 2023 · Inggris · OpenAlex Scopus

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Prasad S. Adusumilli; Marjorie Glass Zauderer; Isabelle Rivière dkk.

Cancer Discovery · 2021 · Inggris · OpenAlex Scopus

Abstract Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous…

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi; William Jacot; Toshinari Yamashita dkk.

New England Journal of Medicine · 2022 · Inggris · OpenAlex Scopus

BACKGROUND: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low"…